Let’s take a look at what info we know now, and
Post# of 36567
(Total Views: 342)
Posted On: 03/02/2021 9:39:57 PM
Let’s take a look at what info we know now, and what has been put out in the past that may be triggered by this transgenic mouse information...this is just the off the top of my head info, so feel free to criticize, discuss or correct...
1. The notion that we have “The Complete Vaccine”
2. We also have a “Complete Booster”
3. Payments triggered from China as no doubt this may (should) have triggered either a next phase of trial or one significant step to gaining the full $65,000,000 due to NGIO once a vaccine is created and achieves regulatory clearance.
4. Bintai Kinden payments (invoices at least)
5. Active further development paid by partners.
I’m of the opinion that the vaccine should be pursued mainly internationally and that an emergency booster using ii-key tech should be fast-tracked. Even partnering with a “major partner” would put us on the right track for US deployment as maneuvering this climate without one of the main players as a partner will be challenging as even though we may have something ready first, it may be delayed in favor of a larger player’s “fast track” due to the perception of them being more proven, then we will find ourselves in a similar position even though we have a clear time advantage for a booster at this point. If I were GNBT I’d put out updates on an international approach to monetization v domestic and this would do two things. One, provide shareholders and stakeholders a valuable update. Two, provide clarity for an execution plan. Hopefully we can hear this officially after we hear that NGIO is uplisted. We are almost to the proverbial land of milk and ii-key vaccines for everyone!
All good things on the “Eve” (using Generex time) of an NGIO Nasdaq listing....hopefully this singular action will end the quiet period!
1. The notion that we have “The Complete Vaccine”
2. We also have a “Complete Booster”
3. Payments triggered from China as no doubt this may (should) have triggered either a next phase of trial or one significant step to gaining the full $65,000,000 due to NGIO once a vaccine is created and achieves regulatory clearance.
4. Bintai Kinden payments (invoices at least)
5. Active further development paid by partners.
I’m of the opinion that the vaccine should be pursued mainly internationally and that an emergency booster using ii-key tech should be fast-tracked. Even partnering with a “major partner” would put us on the right track for US deployment as maneuvering this climate without one of the main players as a partner will be challenging as even though we may have something ready first, it may be delayed in favor of a larger player’s “fast track” due to the perception of them being more proven, then we will find ourselves in a similar position even though we have a clear time advantage for a booster at this point. If I were GNBT I’d put out updates on an international approach to monetization v domestic and this would do two things. One, provide shareholders and stakeholders a valuable update. Two, provide clarity for an execution plan. Hopefully we can hear this officially after we hear that NGIO is uplisted. We are almost to the proverbial land of milk and ii-key vaccines for everyone!
All good things on the “Eve” (using Generex time) of an NGIO Nasdaq listing....hopefully this singular action will end the quiet period!
(4)
(0)